Fariza Shokubayeva

Fariza Shokubayeva

Auto-generated profile, based on publicly available information

Fariza Shokubayeva

National Research Oncology Center

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2026 in Astana Medical Journal
Verified
Journal Article
Closed access
PDF file
AKAzat Karabekov
Azat Karabekov
VKVadim Kemaykin
Vadim Kemaykin
ZBZhandos Burkitbayev
Zhandos Burkitbayev
DZDinara Zharlyganova
Dinara Zharlyganova
IBInna Berger
Inna Berger
ASAidana Shalkarbekova
Aidana Shalkarbekova
Background.Multiple myeloma (MM) is a heterogeneous hematologic malignancy with variable clinical course and response to therapy [1,2]. Unfortunately, MM is still an incurable disease, and the difference in overallsurvival(OS) and progressive free surviva l (PFS) rates in patients varies depending on the risk group. Due to the limited access to high-tech molecular genetic studies for risk group stratification, it remains relevant to study more accessible prognostic markers, in particular based on flow cytometry data [1,8].Aim.In our study, our goal was to evaluate the level of CD56 expression on pathological plasma cells and their effect on the frequency of objective response to induction therapy and overall survival rates in patients with newly diagnosed MM.Materials and Methods.We conducted a retrospective single-center analysis of 26 newly diagnosed MM patients treated at the National Research Oncology Center in Astana, Kazakhstan. For immunophenotyping of plasma cells, we employed multicolor flow cytometry following the standardized EuroFlow protocol with its recommended antibody panels[7,17]. Only patients with ≥10% clonal plasma cells and an aberrant immunophenotype were included, in accordance with international recommendations [4,7,13]. Patients were stratified according to CD56 expression level. All patients received VCD induction therapy. Response was evaluated according to IMWG criteria, and OS was analyzed using Kaplan–Meier curves [3,11]. Results.High objective response rates and 100% overall survival at 24 months were observed in patients with CD56 expression ≤30%, while patients with negative CD56 expression and those with CD56 expression >30% were more likely to experience primary refractoriness and a tendency toward lower overall survival. However, in our study, the differences did not reach statistical significance (p=0.31), possibly due to the limited patient sample, but we do see a trend toward worse outcomes.Conclusion.CD56 expression is an accessible additional prognostic marker and may be used for treatment personalization in patients with multiple myeloma.Keywords:multiple myeloma, CD56, flow cytometry, immunophenotyping, prognosis.

23 October 2026 in Astana Medical Journal
Verified
Journal Article
Closed access
ИМИван Мишутин
Иван Мишутин
VKVadim Kemaykin
Vadim Kemaykin
AKAzat Karabekov
Azat Karabekov
AKAleksandr Kolesnev
Aleksandr Kolesnev
FSFariza Shokubayeva
Fariza Shokubayeva
ZBZhandos Burkitbayev
Zhandos Burkitbayev
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed and refractory hematologic malignancies but can cause rapidly progressive inflammatory, neurologic, infectious, hematologic, cardiovascular, respiratory, and renal complications with overlapping clinical manifestations. This review aimed to synthesize current evidence on their early diagnosis, monitoring, critical care, and interdisciplinary management. A targeted narrative search was conducted in PubMed, including MEDLINE-indexed records, Google Scholar, and websites of international professional societies; the last search was performed on 30 September 2026. The structured PubMed strategy retrieved 4,178 records. Publications from January 2016 through September 2026 were considered, together with two earlier foundational guidelines on febrile neutropenia and acute kidney injury. Thirty-five sources were included after title/abstract screening and targeted full-text assessment. The review addresses cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, infection and sepsis, acute organ dysfunction, prolonged cytopenias, and secondary immunodeficiency. Standardized toxicity grading, serial neurologic assessment, and continuous evaluation of hemodynamics, oxygenation, fluid balance, renal function, coagulation, ferritin, fibrinogen, blood cell counts, and microbiological findings are central to early recognition of deterioration. Fever and organ dysfunction require simultaneous evaluation for immune-mediated toxicity and infection because these conditions may coexist and no single biomarker reliably excludes sepsis. Management should combine syndrome-directed anti-inflammatory treatment, prompt empirical antimicrobial therapy when indicated, and timely organ support. Advanced support outside the intensive care unit is an organizational exception rather than an evidence-proven equivalent model and must not delay transfer. Predefined escalation pathways and coordinated multidisciplinary care are essential for safe implementation of CAR T-cell therapy. Keywords: receptors, chimeric antigen, immunotherapy, adoptive, cytokine release syndrome, neurotoxicity syndromes, critical care, sepsis, patient care team.